Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | AHR | P35869 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.63 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008515 | 0.89 | MAPT (0.80) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4888050 | 0.88 | MAPT (1.00) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4007231 | 0.88 | MAPT (0.78) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4891594 | 0.87 | MAPT (0.77) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL14026144 | 0.87 | MAPT (0.77) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL14026142 | 0.84 | MAPK1 (0.72) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4007152 | 0.84 | MAPK1 (0.72) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4890194 | 0.83 | MAPT (0.71) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL4892030 | 0.82 | EIF2AK2 (0.79) | MAPTMAPK1AHRHTTTTBK1 | |
| SCHEMBL2103341 | 0.81 | EGFR (0.82) | MAPTEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1748991-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105761-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | MAPT 2064/4885MAPK1 1945/4885AHR 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.